Rheumatism News and Research

RSS
Rheumatism is a group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat.
Joints of children with chronic inflammatory arthritis contain premature aging of immune cells

Joints of children with chronic inflammatory arthritis contain premature aging of immune cells

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Updated EULAR recommendations for management of rheumatoid arthritis

Updated EULAR recommendations for management of rheumatoid arthritis

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

Aarhus University study reveals that ordinary neutral running shoes function well for new runners

Aarhus University study reveals that ordinary neutral running shoes function well for new runners

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

EULAR announces recipients of Meritorious Service Award

EULAR announces recipients of Meritorious Service Award

Overweight, obese ERA patients require twice as much drug therapy to achieve successful remission

Overweight, obese ERA patients require twice as much drug therapy to achieve successful remission

Ischaemic heart disease patients at risk after 1 week of treatment

Ischaemic heart disease patients at risk after 1 week of treatment

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Data demonstrate benefits of nurse-led programme on patient self-management of RA

Data demonstrate benefits of nurse-led programme on patient self-management of RA

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Using Swiss ball improves walking performance and muscle strength in AS patients

Using Swiss ball improves walking performance and muscle strength in AS patients

One-third of RA patients discontinue therapy within the first year of treatment

One-third of RA patients discontinue therapy within the first year of treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.